These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 32443728)

  • 1. An Elvitegravir Nanoformulation Crosses the Blood-Brain Barrier and Suppresses HIV-1 Replication in Microglia.
    Gong Y; Zhi K; Nagesh PKB; Sinha N; Chowdhury P; Chen H; Gorantla S; Yallapu MM; Kumar S
    Viruses; 2020 May; 12(5):. PubMed ID: 32443728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel elvitegravir nanoformulation for drug delivery across the blood-brain barrier to achieve HIV-1 suppression in the CNS macrophages.
    Gong Y; Chowdhury P; Nagesh PKB; Rahman MA; Zhi K; Yallapu MM; Kumar S
    Sci Rep; 2020 Mar; 10(1):3835. PubMed ID: 32123217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel elvitegravir nanoformulation approach to suppress the viral load in HIV-infected macrophages.
    Gong Y; Chowdhury P; Midde NM; Rahman MA; Yallapu MM; Kumar S
    Biochem Biophys Rep; 2017 Dec; 12():214-219. PubMed ID: 29214223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137).
    Shimura K; Kodama E; Sakagami Y; Matsuzaki Y; Watanabe W; Yamataka K; Watanabe Y; Ohata Y; Doi S; Sato M; Kano M; Ikeda S; Matsuoka M
    J Virol; 2008 Jan; 82(2):764-74. PubMed ID: 17977962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain.
    Asahchop EL; Meziane O; Mamik MK; Chan WF; Branton WG; Resch L; Gill MJ; Haddad E; Guimond JV; Wainberg MA; Baker GB; Cohen EA; Power C
    Retrovirology; 2017 Oct; 14(1):47. PubMed ID: 29037245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting parenteral combination antiretroviral loaded nano-drug delivery system to treat chronic HIV-1 infection: A humanized mouse model study.
    Mandal S; Kang G; Prathipati PK; Fan W; Li Q; Destache CJ
    Antiviral Res; 2018 Aug; 156():85-91. PubMed ID: 29885378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
    Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
    Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using microfluidic platforms to develop CNS-targeted polymeric nanoparticles for HIV therapy.
    Martins C; Araújo F; Gomes MJ; Fernandes C; Nunes R; Li W; Santos HA; Borges F; Sarmento B
    Eur J Pharm Biopharm; 2019 May; 138():111-124. PubMed ID: 29397261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation, characterization, and safety evaluation of poly(lactide-co-glycolide) nanoparticles for protein delivery into macrophages.
    Guedj AS; Kell AJ; Barnes M; Stals S; Gonçalves D; Girard D; Lavigne C
    Int J Nanomedicine; 2015; 10():5965-79. PubMed ID: 26445538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Suppression of HIV in Myeloid Cells by the BRD4-Selective Small Molecule Modulator ZL0580.
    Alamer E; Zhong C; Liu Z; Niu Q; Long F; Guo L; Gelman BB; Soong L; Zhou J; Hu H
    J Virol; 2020 May; 94(11):. PubMed ID: 32188727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noncovalent PEG Coating of Nanoparticle Drug Carriers Improves the Local Pharmacokinetics of Rectal Anti-HIV Microbicides.
    Nunes R; Araújo F; Barreiros L; Bártolo I; Segundo MA; Taveira N; Sarmento B; das Neves J
    ACS Appl Mater Interfaces; 2018 Oct; 10(41):34942-34953. PubMed ID: 30234288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.
    Satheesan S; Li H; Burnett JC; Takahashi M; Li S; Wu SX; Synold TW; Rossi JJ; Zhou J
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elvitegravir concentrations in seminal plasma in HIV-1-infected men.
    Imaz A; Niubó J; Kashuba AD; Ferrer E; Sykes C; Rozas N; Acerete L; Vila A; Podzamczer D
    HIV Med; 2017 Mar; 18(3):225-230. PubMed ID: 27477062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.
    Kanmogne GD; Singh S; Roy U; Liu X; McMillan J; Gorantla S; Balkundi S; Smith N; Alnouti Y; Gautam N; Zhou Y; Poluektova L; Kabanov A; Bronich T; Gendelman HE
    Int J Nanomedicine; 2012; 7():2373-88. PubMed ID: 22661891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule ONC201 inhibits HIV-1 replication in macrophages via FOXO3a and TRAIL.
    Zhao R; Li Y; Gorantla S; Poluektova LY; Lin H; Gao F; Wang H; Zhao J; Zheng JC; Huang Y
    Antiviral Res; 2019 Aug; 168():134-145. PubMed ID: 31158413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.
    Mandal S; Prathipati PK; Kang G; Zhou Y; Yuan Z; Fan W; Li Q; Destache CJ
    AIDS; 2017 Feb; 31(4):469-476. PubMed ID: 28121666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luminescent PLGA Nanoparticles for Delivery of Darunavir to the Brain and Inhibition of Matrix Metalloproteinase-9, a Relevant Therapeutic Target of HIV-Associated Neurological Disorders.
    Latronico T; Rizzi F; Panniello A; Laquintana V; Arduino I; Denora N; Fanizza E; Milella S; Mastroianni CM; Striccoli M; Curri ML; Liuzzi GM; Depalo N
    ACS Chem Neurosci; 2021 Nov; 12(22):4286-4301. PubMed ID: 34726377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing the delivery of anti retroviral drug "Saquinavir" across the blood brain barrier using nanoparticles.
    Mahajan SD; Roy I; Xu G; Yong KT; Ding H; Aalinkeel R; Reynolds J; Sykes D; Nair BB; Lin EY; Prasad PN; Schwartz SA
    Curr HIV Res; 2010 Jul; 8(5):396-404. PubMed ID: 20426757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model.
    Prathipati PK; Mandal S; Pon G; Vivekanandan R; Destache CJ
    Pharm Res; 2017 Dec; 34(12):2749-2755. PubMed ID: 28905173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functionalized PLGA nanoparticles prepared by nano-emulsion templating interact selectively with proteins involved in the transport through the blood-brain barrier.
    Monge M; Fornaguera C; Quero C; Dols-Perez A; Calderó G; Grijalvo S; García-Celma MJ; Rodríguez-Abreu C; Solans C
    Eur J Pharm Biopharm; 2020 Nov; 156():155-164. PubMed ID: 32927077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.